Oncology · Colorectal CancerOtherclinicalmid-term

SEPTIN9 methylation in ctDNA predicts MRD in colorectal cancer patients post-surgery

Importance8/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/19/2026, 6:02:14 AM

Assessment confidence: 70% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The identification of SEPTIN9 methylation as a predictive biomarker for minimal residual disease in colorectal cancer could significantly influence treatment protocols and patient management. Pharma companies should consider the implications for their clinical strategies in CRC therapies, particularly regarding MRD monitoring. Regulatory context from FDA (Other | Cancer Accelerated Approvals) supports the near-term read. Assessment grounded in 12 ranked evidence items (8 high-relevance).

Strategic Assessment

Pharma companies developing CRC therapies may need to consider integrating MRD monitoring into their clinical strategies. The strongest clinical anchor is Bioelectrical Impedance Analysis for Perioperative Fluid Evaluation in Colorectal Cancer Surgery (ClinicalTrials.gov), sub-indication match (colorectal cancer). In colorectal cancer, 4 regulatory and 0 competitive items passed relevance filtering for colorectal cancer therapies.

Competitive Pressure

The most relevant competitive pressure comes from This finding could enhance early detection strategies for MRD, impacting treatment decisions and patient management in CRC..

Regulatory Outlook

Regulatory risk is concentrated around Other | Cancer Accelerated Approvals (FDA). Regulatory pathway relevance (approval). If SEPTIN9 is validated as a standard biomarker, it may necessitate updates to clinical trial designs and regulatory submissions for CRC therapies, impacting approval timelines.

Key Risks

Elevated medium regulatory exposure for colorectal cancer therapies could delay market entry or constrain labeling if agency review intensifies.
Signal severity is high — leadership review is warranted.

Key Opportunities

Integrating MRD monitoring could enhance the value proposition of CRC therapies, potentially improving market share and patient outcomes. Companies that adapt early may gain a competitive edge.
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications with postmarketing trials that have verified clinical benefit and for which traditional approval has been subsequently granted for the specific indication.
Pharma companies developing CRC therapies may need to consider integrating MRD monitoring into their clinical strategies.

What Would Change This Assessment

This becomes more urgent if Monitor further validation studies and potential clinical adoption of SEPTIN9 as a standard biomarker for MRD in CRC.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Other | Cancer Accelerated Approvals
FDAmedium relevance
Regulatory pathway relevance (approval)
FDA document
View source
Verified Clinical Benefit | Cancer Accelerated Approvals
FDAmedium relevance
Regulatory pathway relevance (approval)
FDA document
View source
Withdrawn | Cancer Accelerated Approvals
FDAmedium relevance
Regulatory pathway relevance (approval)
FDA document
View source
FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer
MHRAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Bioelectrical Impedance Analysis for Perioperative Fluid Evaluation in Colorectal Cancer Surgery
ClinicalTrials.govhigh relevance
Sub-indication match (colorectal cancer)
FDA document
View source
Combination of CT and Ultrasound Radiomics Combined With Liquid Biopsy to Predict Neoadjuvant Chemotherapy Response in Patients With Locally Advanced Gastric Cancer
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Collection of Blood From Patients With Cancer
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Novel MOF P/ZnO Nanocomposite Shows Promise for Targeted Cancer Therapy
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

Early prediction of minimal residual disease in colorectal cancer via SEPTIN9 methylation status in circulating tumor DNA.
PubMedhigh relevance
Sub-indication match (colorectal cancer)
FDA document
View source
Pooled analysis of 2 clinical trials of first-line chemoimmunotherapy for metastatic microsatellite stable colorectal cancer MEDITREME and METIMMOX studies.
PubMedhigh relevance
Sub-indication match (colorectal cancer)
FDA document
View source
An orthotopic organoid-based model to study early CD8⁺ T cell dysfunction and immunotherapy response in colorectal cancer.
PubMedhigh relevance
Sub-indication match (colorectal cancer)
FDA document
View source
ADAR1-circRAB5A-BIP axis governs radiotherapy resistance in colorectal cancer through coordinating protective autophagy and apoptosis.
PubMedhigh relevance
Sub-indication match (colorectal cancer)
FDA document
View source
Immune evasion in locally advanced mismatch repair-deficient microsatellite instability-high colorectal cancer: Reduced T-cell infiltration and upregulation of epithelial IDO1 expression.
PubMedhigh relevance
Sub-indication match (colorectal cancer)
FDA document
View source
Colorectal cancer care in Uganda: a narrative review and case-based health needs assessment from Mbarara Regional Referral Hospital.
PubMedhigh relevance
Sub-indication match (colorectal cancer)
FDA document
View source
Risk Factors, Cancer Types and Prognostic Significance of Second Primary Cancer After Early-, Intermediate- and Late-Onset Colorectal Cancer: A Retrospective Study in Chinese High-Volume Cancer Center
PubMedhigh relevance
Sub-indication match (colorectal cancer)
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

colorectal cancer therapies
oncology clinical trials

Commercial impact

medium

Integrating MRD monitoring could enhance the value proposition of CRC therapies, potentially improving market share and patient outcomes. Companies that adapt early may gain a competitive edge.

Regulatory impact

medium

If SEPTIN9 is validated as a standard biomarker, it may necessitate updates to clinical trial designs and regulatory submissions for CRC therapies, impacting approval timelines.

What to watch

Monitor further validation studies and potential clinical adoption of SEPTIN9 as a standard biomarker for MRD in CRC.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.